Emgality Archives -

UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for

NICE backs Lilly’s Emgality for migraine, adding pressure on Novartis

https://pharmaphorum.com/news/nice-backs-lillys-emgality-for-migraine-adding-pressure-on-novartis-rival/

An EMA advisory panel has rejected expanding the use of Eli Lilly’s Emgality to include prevention of episodic

CHMP turns down Lilly’s Emgality for cluster headache

https://pharmaphorum.com/news/chmp-turns-down-lillys-emgality-for-cluster-headache/

Eli Lilly’s third-to-market migraine prevention drug Emgality has a lot of ground to make up on its rivals,

Lilly firms up case for Emgality in migraine market chase

https://pharmaphorum.com/news/lilly-firms-up-case-for-emgality-in-migraine-market-chase/

Christi Shaw, president of Eli Lilly Bio-Medicines is leaving the company after two years, taking the top job

Lilly dips as biomed chief Christi Shaw heads to Gilead

https://pharmaphorum.com/news/lilly-dips-as-biomed-chief-christi-shaw-heads-to-gilead/

The FDA has approved Eli Lilly’s Emgality (galcanezumab-gnlm) for the treatment of episodic cluster headache in adults, giving

Lilly’s migraine drug gets key cluster headache approval

https://pharmaphorum.com/news/lillys-migraine-drug-gets-key-cluster-headache-approval/

Eli Lilly has a battle on its hands in the migraine prevention category with third-to-market CGRP inhibitor Emgality

Lilly claims fast FDA review for Emgality in cluster headache

https://pharmaphorum.com/news/lilly-claims-fast-fda-review-for-emgality-in-cluster-headache/

Eli Lilly are gearing up to announce details from the latest Emgality analysis, which can potentially push the

Lilly joins CGRP race to cure migraine

https://pharmaphorum.com/news/lilly-joins-cgrp-race-to-cure-migraine/

Emgality